Kymera Therapeutics Executive Compensation (FY25)
KYMR · Executive and director compensation, fiscal 2025 only
The paid brief on Kymera Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (8-K): June 24, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
191 figures on this page: 186 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
More on Kymera Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Kymera Therapeutics' chief executive and what were they paid?
Nello Mainolfi, Founder, President and Chief Executive Officer, received $8,545,609 in total compensation for fiscal 2025.
What was Kymera Therapeutics' say-on-pay result?
Shareholders recorded 96.8% support for the say-on-pay proposal at the meeting held June 24, 2026 for fiscal 2025.
Which companies are in Kymera Therapeutics' peer group?
The disclosed peer group includes ApogeeTherapeutics, Arcellx, Avidity Biosciences, Beam Therapeutics and Biohaven, among others.
What is Kymera Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 21:1, against median employee compensation of $409,607.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Nello Mainolfi Founder, President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brian Adams Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Noah Goodman Chief Business Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jared Gollob Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Bruce Jacobs Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Brian Adams | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Brian Adams | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Bruce Jacobs | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Bruce Jacobs | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jared Gollob | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jared Gollob | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| MBA | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| MBA | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nello Mainolfi | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Bruce Jacobs | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/28/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/28/2033 | |
| Option | ◇ | — | ◇ | 3/2/2035 | |
| Jared Gollob | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/2/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/28/2033 | |
| Option | ◇ | — | ◇ | 2/28/2034 | |
| Nello Mainolfi | Option | ◇ | — | ◇ | 3/2/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/28/2034 | |
| Option | ◇ | — | ◇ | 2/28/2033 | |
| Option | ◇ | — | ◇ | 3/2/2035 | |
| Brian Adams | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 9/2/2035 | |
| Noah Goodman | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 4/7/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Brian Adams
Chief Legal Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Bruce Jacobs
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Jared Gollob
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Nello Mainolfi
Founder, President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Noah Goodman
Chief Business Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Jeffrey Albers | ◇ | — | ◇ | — | — | — | ◇ |
Felix J. Baker | ◇ | — | ◇ | — | — | — | ◇ |
Elena Ridloff | ◇ | — | ◇ | — | — | — | ◇ |
Pamela Esposito | ◇ | — | ◇ | — | — | — | ◇ |
John Maraganore | ◇ | — | ◇ | — | — | — | ◇ |
Gorjan Hrustanovic | ◇ | — | ◇ | — | — | — | ◇ |
Gorjan Hrustanovic Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Leigh Morgan | ◇ | — | — | — | — | — | ◇ |
Bruce Booth, Nello Mainolfi and Victor Sandor served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ApogeeTherapeutics symbol not shown
- Arcellx ACLX
- Avidity Biosciences RNA
- Beam Therapeutics BEAM
- Biohaven BHVN
- Denali Therapeutics DNLI
- Dyne Therapeutics DYN
- IDEAYA Biosciences IDYA
- ImmunityBio IBRX
- Immunovant IMVT
- Nuvalent NUVL
- Protagonist Therapeutics PTGX
- Vaxcyte PCVX
- Vera Therapeutics VERA
- Viking Therapeutics VKTX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 24, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 25, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 18, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Kymera Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kymera Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
191 figures on this page: 186 cited to the filing that reported them, 5 calculated from figures it prints.
186 cited to the filing
5 calculated from the filing
Documents cited
- 0001193125-26-281051Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-1914952025 Summary Compensation Table · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · and 1 more section
- 0001193125-25-151345Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-24-164550Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-23-168977Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-175498Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kymera Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/KYMR (accessed 2026).
Short form: data: Velarion
The paid brief for Kymera Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kymera Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Kymera Therapeutics discloses
The companies named in KYMR's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}